Dr. Reddy's: No looking back - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr. Reddy's: No looking back

May 30, 2001

Dr. Reddy's has recorded a net profit of Rs 1.3 bn in FY01. The results for the current year include consolidated figures for Cheminor Drugs and hence are not comparable with FY00. Operating profit margins have showed a marked improvement compared to our projections.

(Rs m)FY00FY01% change
Sales 4,930 8,324 68.8%
Other Income 49 161228.6%
Expenditure 4,001 6,048 51.2%
Operating Profit (EBDIT) 929 2,276 145.0%
Operating Profit Margin (%)18.8%27.3%
Interest 141 358 153.9%
Depreciation 169 437 158.6%
Profit before Tax 668 1,642 145.8%
Tax 65 300 361.5%
Profit after Tax/(Loss) 603 1,342 122.6%
Net profit margin (%)12.2%16.1%
No. of Shares (eoy) (m)26.537.4
Diluted Earnings per share*22.835.9
P/E (at current price)62.139.4
(* after ADR dilution)

On a comparative basis, net profit has improved by 54% on the back of a 25% increase in gross turnover. Exports now account for almost 50% of the total turnover on a consolidated basis. Operating profit margins have shown a marked improvement of more than 600 basis points on a comparative basis. The net profit declared by the company is more or less as per market expectations.

R&D expenses showed a noteworthy increase of 87% to 610 m, constituting 7% of turnover. Dr. Reddy announced a licensing agreement with Novartis Pharma AG for its anti-diabetic molecule against which the company would receive US$ 55 m as up-front and milestone payments. Besides, the company also has a very strong R&D coffer, which is expected to deliver results in the time to come.

Dr. Reddy is targeting huge US generic market for rapid growth. The generic business unit has contributed a maiden Rs 300 m in FY01. Cheminor Drugs (now merged with Dr. Reddy) has a string of generic products in the pipeline for the lucrative US markets. In a related development, the company has recently received ANDA approval for marketing generic version of Famotidine. Dr. Reddy has filed for a six month generic marketing exclusivity for fluoxetine, an anti-depression drug with the US FDA. We expect that Dr. Reddy's may mop up an additional US$ 40 m revenues in FY02 if its able to bag the six month exclusivity rights. Dr. Reddy stands a strong chance of getting the exclusive rights.

The company has recently raised US$ 115.5 m from ADR proceeds, diluting 18% of the company's equity. It plans to use these proceeds for R&D (US$ 30 m) and acquisitions to fuel inorganic growth. We expect that with ADR fund deployment and milestone receipts the company would be able to take a step towards self sufficiency in its R&D work.

At the current market price of Rs 1,413 the company is trading at a P/E of 40 times its fully diluted earnings for FY01 earnings (after taking into account ADR dilution). There are number of valuation triggers for the company at this point of time viz. windfall revenue gains from its research pipeline, US generic market earnings visibility, inorganic growth from ADR funds, further unlocking of intellectual property, strong core business fundamentals etc. However, at 40 times its FY01 earnings, the markets seem to have built in lot of expectations from the company. The flip side thus is that any negative news either from the US generic market or on the R&D front could lead to a fall in valuations. Again, any delay in deployment of ADR funds, could impact Return on capital employed (ROCE) negatively in the near term.

Equitymaster requests your view! Post a comment on "Dr. Reddy's: No looking back". Click here!


More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 3, 2021 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks